TY - JOUR
T1 - Evidence-Based Guideline for the management of osteoporosis in men
AU - Fuggle, Nicholas R.
AU - Beaudart, Charlotte
AU - Bruyere, Olivier
AU - Abrahamsen, Bo
AU - Al-Daghri, Nasser
AU - Burlet, Nansa
AU - Chandran, Manju
AU - Rosa, Mario M.
AU - Cortet, Bernard
AU - Demonceau, Celine
AU - Dere, Willard
AU - Halbout, Philippe
AU - Hiligsmann, Mickael
AU - Kanis, John A.
AU - Kaufman, Jean-Marc
AU - Kurth, Andreas
AU - Lamy, Olivier
AU - Laslop, Andrea
AU - Maggi, Stefania
AU - Matijevic, Radmila
AU - Mccloskey, Eugene
AU - Mobasheri, Ali
AU - Prieto Yerro, Maria C.
AU - Radermecker, Regis P.
AU - Sabico, Shaun
AU - Al-Saleh, Yousef
AU - Silverman, Stuart
AU - Veronese, Nicola
AU - Rizzoli, Rene
AU - Cooper, Cyrus
AU - Reginster, Jean-Yves
AU - Harvey, Nicholas C.
PY - 2024/4
Y1 - 2024/4
N2 - Historically, osteoporosis has been viewed as a disease of women, with research, trials of interventions and guidelines predominantly focused as such. It is apparent, however, that this condition causes a substantial health burden in men also, and that its assessment and management must ultimately be addressed across both sexes. In this article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents GRADE-assessed recommendations for the diagnosis, monitoring and treatment of osteoporosis in men. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its associated high fracture risk in men, covering disease burden, appropriate interpretation of bone densitometry (including the use of a female reference database for densitometric diagnosis in men) and absolute fracture risk, thresholds for treatment, and interventions that can be used therapeutically and their health economic evaluation. Future work should specifically address the efficacy of anti-osteoporosis medications, including denosumab and bone-forming therapies.
AB - Historically, osteoporosis has been viewed as a disease of women, with research, trials of interventions and guidelines predominantly focused as such. It is apparent, however, that this condition causes a substantial health burden in men also, and that its assessment and management must ultimately be addressed across both sexes. In this article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents GRADE-assessed recommendations for the diagnosis, monitoring and treatment of osteoporosis in men. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its associated high fracture risk in men, covering disease burden, appropriate interpretation of bone densitometry (including the use of a female reference database for densitometric diagnosis in men) and absolute fracture risk, thresholds for treatment, and interventions that can be used therapeutically and their health economic evaluation. Future work should specifically address the efficacy of anti-osteoporosis medications, including denosumab and bone-forming therapies.
KW - TRABECULAR BONE SCORE
KW - FRACTURE RISK REDUCTION
KW - COST-UTILITY ANALYSIS
KW - HIP FRACTURE
KW - OLDER MEN
KW - POSTMENOPAUSAL WOMEN
KW - PARATHYROID-HORMONE
KW - ZOLEDRONIC ACID
KW - MINERAL DENSITY
KW - EUROPEAN-SOCIETY
U2 - 10.1038/s41584-024-01094-9
DO - 10.1038/s41584-024-01094-9
M3 - (Systematic) Review article
SN - 1759-4790
VL - 20
SP - 241
EP - 251
JO - Nature Reviews Rheumatology
JF - Nature Reviews Rheumatology
IS - 4
ER -